Jinling Pharmaceutical Company Limited (000919.SZ)
- Previous Close
6.67 - Open
6.62 - Bid 6.62 x --
- Ask 6.63 x --
- Day's Range
6.62 - 6.77 - 52 Week Range
5.55 - 7.85 - Volume
8,623,410 - Avg. Volume
7,789,610 - Market Cap (intraday)
4.135B - Beta (5Y Monthly) 0.57
- PE Ratio (TTM)
331.50 - EPS (TTM)
0.02 - Earnings Date --
- Forward Dividend & Yield 0.10 (1.50%)
- Ex-Dividend Date May 31, 2024
- 1y Target Est
--
Jinling Pharmaceutical Company Limited manufactures and sells pharmaceutical products and medical devices in China. The company provides Mailuoning injection/oral solutions for the treatment of thromboangiitis obliterans, arteriosclerosis obliterans, cerebral thrombosis and sequelae, polyarteritis, acute arterial embolism of extremities, diabetic gangrene, intravenous thrombus, thrombophlebitis, etc.; ferrous succinate tablets for the prevention and treatment of iron deficiency anemia; lentinan injection for the treatment of malignant tumors; and absorbable gelatin sponges for the treatment of wound hemostasis. It also offers medical and health care services. Jinling Pharmaceutical Company Limited was founded in 1998 and is headquartered in Nanjing, China.
jlyy1999.com5,789
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 000919.SZ
View MorePerformance Overview: 000919.SZ
Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 000919.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 000919.SZ
View MoreValuation Measures
Market Cap
4.16B
Enterprise Value
1.98B
Trailing P/E
387.79
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.27
Price/Book (mrq)
1.09
Enterprise Value/Revenue
0.61
Enterprise Value/EBITDA
303.62
Financial Highlights
Profitability and Income Statement
Profit Margin
0.56%
Return on Assets (ttm)
-0.17%
Return on Equity (ttm)
-0.17%
Revenue (ttm)
3.25B
Net Income Avi to Common (ttm)
18.27M
Diluted EPS (ttm)
0.02
Balance Sheet and Cash Flow
Total Cash (mrq)
2.6B
Total Debt/Equity (mrq)
3.89%
Levered Free Cash Flow (ttm)
-43.89M